GlassScriptPhysician profile
Dawn K King
NPI 1568413763
$7,637.86
in general payments reported to CMS, 2019-2025
34 companies · $2,767 in 2025
The $2,767 reported for 2025 was more than what 85% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $355 · 2021: $445 · 2022: $1,196 · 2023: $1,043 · 2024: $1,022 · 2025: $2,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,143 · Travel and Lodging: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,143.45 |
| Travel and Lodging | $688.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,254.19 | 2021-2025 | Interstim, Altaviva |
| Abbvie INC. | $652.99 | 2019-2025 | |
| Medtronic USA, INC. | $470.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $341.86 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Depuy Synthes Sales INC. | $333.78 | 2019-2025 | |
| Astellas Pharma US INC | $325.84 | 2019-2025 | Padcev, Myrbetriq, Veozah |
| Janssen Biotech, INC. | $313.03 | 2019-2025 | Erleada, Akeega, Balversa |
| Sumitomo Pharma America, INC. | $266.92 | 2023-2025 | Gemtesa, Orgovyx |
| Allergan, INC. | $234.16 | 2019-2021 | |
| Pfizer INC. | $167.15 | 2020-2025 | |
| Urogen Pharma, INC. | $161.72 | 2022-2025 | Jelmyto |
| Urogpo LLC | $114.54 | 2019 | |
| Accord Healthcare, INC. | $110.93 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $110.01 | 2023-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $100.39 | 2022-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $78.54 | 2024-2025 | Xiaflex, Aveed |
| Amgen INC. | $78.17 | 2019-2022 | |
| Immunitybio, INC. | $73.67 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $68.59 | 2022-2025 | Lynparza |
| Genzyme Corporation | $53.39 | 2022-2023 | |
| Ambu INC. | $49.66 | 2023 | |
| Myovant Sciences INC. | $48.43 | 2022 | |
| Endo Pharmaceuticals INC. | $44.45 | 2022-2023 | Aveed, Xiaflex |
| Bluewind Medical | $39.31 | 2025 | Revi |
| Ferring Pharmaceuticals INC. | $32.44 | 2024-2025 | Adstiladrin |
| Rochester Medical Corporation | $18.36 | 2022 | |
| Agiliti Surgical, INC. | $17.74 | 2020 | |
| Sun Pharmaceutical Industries INC. | $16.09 | 2023 | Yonsa |
| Verity Pharmaceuticals INC. | $15.54 | 2024 | Trelstar |
| Tolmar Pharmaceuticals, INC. | $14.43 | 2022 | |
| Boston Scientific Corporation | $14.17 | 2021 | |
| Urovant Sciences INC | $13.02 | 2022 | |
| Travere Therapeutics, INC. | $3.82 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$239,478.70 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.